If your psoriatic arthritis symptoms are severe, your doctor may prescribe you a biologic. These are a newer type of DMARD that are made using molecular biology techniques. Biologics block ...

Bimekizumab-bkzx (Bimzelx) is now FDA approved for 4 chronic immune-mediated inflammatory diseases: psoriatic arthritis, nonradiographic axial spondyloarthritis (axSpA), ankylosing spondylitis, and ...

Currently available biologics have revolutionized the management ... extended-oligoarticular and juvenile psoriatic arthritis with polyarticular involvement. Efficacy of infliximab is less ...

The US Food and Drug Administration has approved bimekizumab -bkzx (Bimzelx; UCB) for adult patients with active psoriatic ...

“In psoriatic arthritis and across the spectrum of axSpA ... Bimzelx’s launch in psoriasis has been “the strongest” in the ...

With more than 300 patients in the trial, dubbed FOREMOST, 33.9% of those assigned to apremilast achieved minimal disease ...

The Food and Drug Administration (FDA) has expanded the approval of Bimzelx ® (bimekizumab-bkzx) to include 3 new indications. In addition to plaque psoriasis, Bimzelx, a humanized interleukin-17A and ...

Tremfya is a prescription drug used for psoriasis and psoriatic arthritis. Find out about possible interactions with alcohol, ...

The decision to use b/tsDMARD monotherapy vs combination therapy with MTX when treating PsA is primarily based on patient satisfaction and drug tolerability.

Despite being diagnosed with juvenile arthritis at age 2, as an adult Meaghan struggled to find a doctor who would take her ...

One in four participants in a European wide study aimed at detecting early signs of psoriasis showed signs of possible ...

Access to adequate care for psoriasis is inconsistent across Europe and the condition remains misunderstood and undertreated.